Compare Abbott Laboratories (ABT) vs Cognizant Technology Solutions Corp (CTSH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Cognizant Technology Solutions Corp — how do they compare? Abbott Laboratories trades at $95.13 (market cap $166.94B), while Cognizant Technology Solutions Corp trades at $42.43 (market cap $20.78B). The key difference: Abbott Laboratories is far larger — about 8× Cognizant Technology Solutions Corp's market cap, and Cognizant Technology Solutions Corp pays the higher dividend (3%). Which is the better fit depends on your goals.
| ABT | CTSH | |
|---|---|---|
Market Cap | $166.94B | $20.78B |
Sector | Health | Technology |
52-Week High | $136.62 | $86.70 |
52-Week Low | $82.57 | $38.73 |
Enterprise Value | $193.69B | $20.36B |
Dividend Yield | 2.63% | 3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Cognizant Technology Solutions (CTSH) trades at $43.94, up 4.64% today, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with a P/E of 8.97 and net margin of 10.41%, supported by $21.11B revenue in 2025. Recent news highlights AI partnerships with Google Cloud and OpenAI, positioning CTSH for growth in enterprise AI solutions.
Outlook remains positive with a consensus price target of $67.58, implying 54% upside, though near-term risks include soft IT demand and margin pressures. Institutional sentiment is mixed with 43% buy ratings, but the valuation discount and AI expansion present a compelling opportunity for long-term investors amid sector volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Cognizant Technology Solutions Corp
Cognizant is a global IT services provider, offering consulting and outsourcing services to some of the world's largest enterprises spanning the financial services, media and communications, healthcare, natural resources, and consumer products industries. Cognizant employs nearly 300,000 people globally, roughly 70% of whom are in India, although the company's headquarters are in Teaneck, New Jersey.
Read more on CTSH →
